Inspira Technologies Oxy BHN (IINN) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Inspira Technologies Oxy BHN Ltd. has announced its intention to report clinical results for its innovative HYLA™ blood sensor in the fourth quarter of 2024, targeting the $2.5 billion Point of Care and ABG analyzer market. The HYLA™ sensor, which enables real-time monitoring of blood parameters during open-heart surgery, is a key part of Inspira’s long-term growth strategy and is expected to integrate with the FDA-cleared INSPIRA™ ART100 systems. Inspira is focusing on expanding its blood testing facilities and developing the HYLA™ sensor line to transform respiratory and life-support sectors, addressing a $59 billion annual market opportunity.
For further insights into IINN stock, check out TipRanks’ Stock Analysis page.
